{
  "id": "58a644e560087bc10a000027",
  "type": "factoid",
  "question": "What is the drug target for Simtuzumab?",
  "ideal_answer": " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23821193",
    "http://www.ncbi.nlm.nih.gov/pubmed/27939076",
    "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
    "http://www.ncbi.nlm.nih.gov/pubmed/27232579"
  ],
  "snippets": [
    {
      "text": " These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other potential agents will be silent information regulator protein Sirtuin and antifibrotic monoclonal antibody Simtuzumab against lysyl oxidase like molecule 2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26085906",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results suggest that LOXL2 could be an appealing target for treatment of scar formation after glaucoma surgery, and point to the potential therapeutic benefits of simtuzumab, a humanized monoclonal antibody derived from GS-607601.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23821193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, i",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27232579",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "LOXL2"
}